News >

Tisagenlecleucel Enhances Health-Related QoL in Relapsed/Refractory DLBCL

Caroline Seymour
Published: Friday, May 22, 2020

Richard T. Maziarz, MD

Richard T. Maziarz, MD

Tisagenlecleucel (Kymriah) led to clinically meaningful and durable improvements in health-related quality of life (HRQoL) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who achieved a complete or partial response (PR) to the CD19-directed CAR T-cell therapy in the phase 2 JULIET trial, according to results of a study published in Blood Advances.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication